United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
| Revenue | $2,877,400,000 |
| Net Income | $1,195,100,000 |
| Free Cash Flow | $1,080,600,000 |
| Book Value / Share | $142.57 |
| Total Liabilities | $920,000,000 |
| Total Equity | $6,444,000,000 |
| Debt / Equity | 0.05 |
| Current Ratio | 5.25 |
| Interest Coverage | 32.10 |
| Working Capital | $3,135,800,000 |
Core multiples and valuation signals — useful to compare vs peers.
| P/E (TTM) | 13.34 |
| Industry P/E | N/A |
| Forward P/E | 15.50 |
| P/B | 2.47 |
| Price / Sales | 5.54 |
| P / FCF | 14.76 |
| EV / EBITDA | 8.80 |
| Graham Number | $291.23 |
| DCF (placeholder) | — |
| Gross Margin | 89.24% |
| Operating Margin | 47.86% |
| Net Margin | 41.53% |
| ROIC | 15.44% |
| Asset Turnover | 0.39 |
| RSI (14) | 56.94 |
| SMA 50 | 380.34 |
| SMA 200 | 332.85 |
| MACD | 15.84 |
| Signal | BULLISH |
| Name | Title |
|---|---|
| Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. | Founder, Chairman & CEO (1955) |
| Mr. Michael I. Benkowitz | President & COO (1972) |
| Mr. James C. Edgemond | CFO & Treasurer (1968) |
| Mr. Paul A. Mahon J.D. | Executive VP, General Counsel & Corporate Secretary (1964) |
| Harrison Silvers | Manager of Investor Relations (—) |
| Ms. Holly Hobson | Associate Vice President of Human Resources (—) |
| Kevin T. Gray | Senior Vice President of Strategic Operations & Logistics (—) |
| Mr. Patrick Poisson | Executive VP of Technical Operations (1968) |
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., October 15, 2025--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time.
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
SILVER SPRING, Md., & RESEARCH TRIANGLE PARK, N.C., October 13, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced two presentations at the upcoming CHEST 2025 Annual Meeting hosted by the American College of Chest Physicians taking place October 19-22, 2025, in Chicago. In addition, United Therapeutics will sponsor and host several events including the PHinding Pulmonary Hypertension: Exploring Best Practices in PH-ILD Detection and Management di